FAX 250MG.CAPS.

Main information

  • Trade name:
  • FAX 250MG.CAPS. 10
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • FAX 250MG.CAPS. 10
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

1-3-2018

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

FDA - U.S. Food and Drug Administration

18-1-2018

Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

Use of a non-sterile injectable product could result in fatal infections.

FDA - U.S. Food and Drug Administration

18-1-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Levofloxacin in 5% Dextrose 250mg/50mL Due to Presence of Visible Particulate Matter Tentatively Identified as Mold

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Levofloxacin in 5% Dextrose 250mg/50mL Due to Presence of Visible Particulate Matter Tentatively Identified as Mold

FOR IMMEDIATE RELEASE – 01-12-2018 – East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level. The product has been found to contain visible particulate matter tentatively identified as mold. This problem was discovered as a result of a product complaint in which the contents of one flexible bag was found to contain whi...

FDA - U.S. Food and Drug Administration

28-12-2017

PPG Architectural Coatings Canada Inc. recalls Olympic Premium Deck Cleaner and CIL Scrub-Free Deck Cleaner

PPG Architectural Coatings Canada Inc. recalls Olympic Premium Deck Cleaner and CIL Scrub-Free Deck Cleaner

The caps on some of the deck cleaner containers do not provide a complete seal. Leaking product has been observed from some caps when the container is not maintained in an upright position and/or the cap does not offer sufficient resistance when opening the container impairing child-resistant characteristics. Improperly functioning packaging could result in unintentional exposure to these products and lead to serious illness, injury or death.

Health Canada

23-5-2017

 The Danish Medicines Agency will be closed on 26 May

The Danish Medicines Agency will be closed on 26 May

The Danish Medicines Agency will be closed on 26 May, the day after Ascension Day. Compassionate use permits However, we process urgent applications for compassionate use permits (applications for dispensing of non-marketed medicines). Physicians, dentists or veterinarians can submit applications electronically by using a NemID employee signature or via fax to +45 44 88 91 17. Please mark the application URGENT. We will be taking questions about compassionate use permits on +45 44 88 95 36 or by mail to...

Danish Medicines Agency

8-2-2018

RENO CAPS (Reno Caps) Capsule [Nnodum Pharmaceuticals]

RENO CAPS (Reno Caps) Capsule [Nnodum Pharmaceuticals]

Updated Date: Feb 8, 2018 EST

US - DailyMed

31-1-2018

Scientific guideline:  Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

30-1-2018

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

Updated Date: Jan 30, 2018 EST

US - DailyMed

17-1-2018

Mvasi (Amgen Europe B.V.)

Mvasi (Amgen Europe B.V.)

Mvasi (Active substance: bevacizumab) - Centralised - Authorisation - Commission Decision (2018)250 of Wed, 17 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4728

Europe -DG Health and Food Safety

29-12-2017

METRONIDAZOLE 250 MG (Metronidazole) Tablet, Film Coated [Vivimed Labs Limited]

METRONIDAZOLE 250 MG (Metronidazole) Tablet, Film Coated [Vivimed Labs Limited]

Updated Date: Dec 29, 2017 EST

US - DailyMed

29-12-2017

K-BROVET 250 (Potassium Bromide) Tablet, Chewable [Pegasus Laboratories, Inc.]

K-BROVET 250 (Potassium Bromide) Tablet, Chewable [Pegasus Laboratories, Inc.]

Updated Date: Dec 29, 2017 EST

US - DailyMed